These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22052223)

  • 21. Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
    Sheikh N; Chambers CR
    J Oncol Pharm Pract; 2013 Sep; 19(3):228-36. PubMed ID: 23175450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
    Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M
    Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
    Arellano J; Leteneux C
    J Med Econ; 2008; 11(2):363-66; author reply 366-70. PubMed ID: 19450092
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
    Chouaid C; Le Caer H; Locher C; Dujon C; Thomas P; Auliac JB; Monnet I; Vergnenegre A;
    BMC Cancer; 2012 Jul; 12():301. PubMed ID: 22817667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
    Hawkins N; Scott DA; Woods BS; Thatcher N
    Value Health; 2009 Sep; 12(6):996-1003. PubMed ID: 19402854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
    Bartminski W
    Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
    Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
    Ramsey SD; Clarke L; Kamath TV; Lubeck D
    J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
    Horgan AM; Bradbury PA; Amir E; Ng R; Douillard JY; Kim ES; Shepherd FA; Leighl NB
    Ann Oncol; 2011 Aug; 22(8):1805-11. PubMed ID: 21273345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
    Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
    Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
    Ng R; Loreto M; Lee R; Leighl NB
    Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
    Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(1):75-92. PubMed ID: 20014878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.